Cargando…

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice

BACKGROUND: The advent of oral disease-modifying therapies fundamentally changed the treatment of multiple sclerosis. Nevertheless, impressions of their relative efficacy and tolerability are primarily founded on expert opinion. OBJECTIVE: The purpose of this study was to determine whether oral dise...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longbrake, Erin E, Cross, Anne H, Salter, Amber
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340186/ https://www.ncbi.nlm.nih.gov/pubmed/28280599 http://dx.doi.org/10.1177/2055217316677868

Ejemplares similares

Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications
por: Levit, Elle, et al.
Publicado: (2022)

An older dog with newer tricks: Predicting efficacy of IFN-β treatment for multiple sclerosis
por: Wu, Gregory F., et al.
Publicado: (2016)

High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
por: Freeman, Léorah, et al.
Publicado: (2022)

Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
por: Porwal, Mokshal H., et al.
Publicado: (2022)

A survey of risk tolerance to multiple sclerosis therapies
por: Fox, Robert J., et al.
Publicado: (2019)

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
por: Zhang, Yinan, et al.
Publicado: (2020)

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
por: Zhang, Yinan, et al.
Publicado: (2021)

Stronger Microstructural Damage Revealed in Multiple Sclerosis Lesions With Central Vein Sign by Quantitative Gradient Echo MRI
por: Levasseur, Victoria A., et al.
Publicado: (2022)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis
por: Earla, Jagadeswara R, et al.
Publicado: (2020)

Clinical trials in multiple sclerosis: milestones
por: Zhang, Yinan, et al.
Publicado: (2018)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies
por: D'Amico, Emanuele, et al.
Publicado: (2021)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
por: Braune, Stefan, et al.
Publicado: (2015)

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry
por: Stuchiner, Tamela, et al.
Publicado: (2020)

Era of COVID-19 in Multiple Sclerosis Care
por: Krett, Jonathan D., et al.
Publicado: (2023)

Evolution of clinical trials in multiple sclerosis
por: Zhang, Yinan, et al.
Publicado: (2019)

Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis
por: Earla, Jagadeswara Rao, et al.
Publicado: (2021)

CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome
por: Choileáin, Siobhán Ní, et al.
Publicado: (2019)

The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
por: Shahtaheri, Rahil Sadat, et al.
Publicado: (2020)

Uptake and Attitudes About Immunizations in People With Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
por: Visser, Leo H, et al.
Publicado: (2016)

Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis
por: Elo, Petri, et al.
Publicado: (2021)

Attitudes of people with multiple sclerosis toward brain donation
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
por: Munsell, Michael, et al.
Publicado: (2016)

Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches
por: Grand′Maison, Francois, et al.
Publicado: (2018)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies
por: Smith, Tyler Ellis, et al.
Publicado: (2021)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
por: Simpson-Yap, Steve, et al.
Publicado: (2021)

Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks
por: Alroughani, Raed, et al.
Publicado: (2016)

Self-tolerance in multiple sclerosis
por: Gonsette, R. E.
Publicado: (2012)

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
por: Fernández, Oscar, et al.
Publicado: (2017)

Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectiveness
por: Järvinen, Elina, et al.
Publicado: (2016)

Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
por: Salter, Amber, et al.
Publicado: (2021)

Etiology, effects and management of comorbidities in multiple sclerosis: recent advances
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pu2ipn8je5ap99vererr9lgc0i